Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alumis Inc. (ALMS), Larimar Therapeutics (LRMR) and ...

Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Larimar Therapeutics (LRMR) and Eli Lilly & Co (LLY)

Citi analyst Samantha Semenkow reiterated a Buy rating on Larimar Therapeutics today and set a price target of $14.00. Semenkow covers the Healthca...

Citi Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

Larimar Therapeutics ( ($LRMR) ) has issued an update. On March 9, 2026, Larimar Therapeutics posted an updated corporate presentation outlining pr...

Market Cap	$292.72M	P/E Ratio	N/A
52W High	$6.42	52W Low	$1.61
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	23.5%	52W Position	72.9%
Overall Score	55	Value Score	60
Quality Score	--	Technical Score	50

EPS Current Est	$-1.93	EPS Next Est	$-1.86
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LRMR	$5.12	+1.49%	1.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LRMR	$5.12	+1.5%	1.02M
3
4
5
6

LRMR

LRMR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Larimar Therapeutics Inc. Data in Excel

Get Larimar Therapeutics Inc. Data in Excel